Sumitomo Mitsui DS Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$81.7M Buy
324,551
+3,394
+1% +$730K 0.56% 42
2026
Q1
$69.8M Buy
321,157
+4,634
+1% +$1.03M 0.56% 38
2025
Q4
$72.3M Buy
316,523
+30,032
+10% +$6.84M 0.57% 38
2025
Q3
$66.3M Buy
286,491
+5,571
+2% +$1.13M 0.54% 41
2025
Q2
$52.1M Buy
280,920
+8,090
+3% +$1.5M 0.47% 48
2025
Q1
$57.2M Buy
272,830
+13,560
+5% +$2.64M 0.58% 38
2024
Q4
$46.1M Buy
259,270
+32,467
+14% +$5.97M 0.47% 45
2024
Q3
$44.8M Buy
226,803
+21,790
+11% +$4.07M 0.48% 43
2024
Q2
$35.2M Buy
205,013
+6,881
+3% +$1.14M 0.42% 49
2024
Q1
$36.1M Buy
198,132
+9,390
+5% +$1.62M 0.45% 46
2023
Q4
$29.2M Buy
188,742
+413
+0.2% +$60.2K 0.38% 56
2023
Q3
$28.1M Buy
188,329
+8,604
+5% +$1.26M 0.44% 52
2023
Q2
$24.2M Buy
179,725
+29,437
+20% +$4.32M 0.37% 57
2023
Q1
$24M Buy
150,288
+8,159
+6% +$1.25M 0.43% 53
2022
Q4
$23M Buy
142,129
+4,803
+3% +$736K 0.47% 52
2022
Q3
$18.4M Buy
137,326
+8,219
+6% +$1.18M 0.42% 56
2022
Q2
$19.8M Sell
129,107
-11,751
-8% -$1.8M 0.47% 50
2022
Q1
$22.8M Buy
140,858
+83
+0.1% +$12.1K 0.48% 44
2021
Q4
$19.1M Buy
140,775
+3,812
+3% +$450K 0.4% 63
2021
Q3
$14.8M Sell
136,963
-1,201
-0.9% -$137K 0.35% 64
2021
Q2
$15.6M Sell
138,164
-1,993
-1% -$224K 0.37% 58
2021
Q1
$15.2M Buy
140,157
+1,674
+1% +$179K 0.4% 57
2020
Q4
$14.8M Buy
138,483
+2,636
+2% +$253K 0.42% 58
2020
Q3
$11.9M Sell
135,847
-2,408
-2% -$227K 0.38% 66
2020
Q2
$13.6M Buy
138,255
+12,525
+10% +$1.1M 0.47% 50
2020
Q1
$9.58M Sell
125,730
-22,733
-15% -$1.94M 0.39% 57
2019
Q4
$13.1M Sell
148,463
-6,554
-4% -$544K 0.45% 51
2019
Q3
$11.7M Buy
155,017
+9,190
+6% +$630K 0.44% 50
2019
Q2
$10.6M Buy
145,827
+6,669
+5% +$524K 0.43% 51
2019
Q1
$11.2M Buy
139,158
+17,444
+14% +$1.43M 0.19% 121
2018
Q4
$11.2M Sell
121,714
-15,600
-11% -$1.37M 0.2% 107
2018
Q3
$13M Sell
137,314
-4,957
-3% -$470K 0.2% 108
2018
Q2
$13.2M Sell
142,271
-5,798
-4% -$566K 0.2% 103
2018
Q1
$14M Sell
148,069
-18,542
-11% -$2.04M 0.21% 103
2017
Q4
$16.1M Buy
166,611
+10,617
+7% +$1M 0.24% 95
2017
Q3
$13.9M Sell
155,994
-4,458
-3% -$339K 0.22% 108
2017
Q2
$11.6M Sell
160,452
-8,780
-5% -$590K 0.19% 119
2017
Q1
$11M Sell
169,232
-23,880
-12% -$1.5M 0.19% 120
2016
Q4
$12.1M Sell
193,112
-35,004
-15% -$2.14M 0.23% 117
2016
Q3
$14.4M Sell
228,116
-26,888
-11% -$1.74M 0.31% 103
2016
Q2
$15.8M Buy
255,004
+28,276
+12% +$1.72M 0.48% 60
2016
Q1
$12.9M Sell
226,728
-9,469
-4% -$528K 0.4% 69
2015
Q4
$14M Sell
236,197
-17,767
-7% -$1.02M 0.47% 61
2015
Q3
$13.8M Buy
253,964
+31,633
+14% +$2.06M 0.47% 54
2015
Q2
$14.9M Sell
222,331
-4,925
-2% -$322K 0.47% 56
2015
Q1
$13.3M Sell
227,256
-60,589
-21% -$3.66M 0.4% 73
2014
Q4
$18.8M Sell
287,845
-16,887
-6% -$1.06M 0.58% 42
2014
Q3
$17.6M Sell
304,732
-16,300
-5% -$905K 0.54% 46
2014
Q2
$18.1M Sell
321,032
-10,046
-3% -$527K 0.52% 46
2014
Q1
$17M Sell
331,078
-36,592
-10% -$1.85M 0.5% 45
2013
Q4
$19.4M Sell
367,670
-54,907
-13% -$2.7M 0.56% 43
2013
Q3
$18.9M Buy
422,577
+96,878
+30% +$4.29M 0.54% 47
2013
Q2
$13.5M Buy
+325,699
New +$14.2M 0.38% 64

Other funds holding ABBV

Sumitomo Mitsui DS Asset Management's ABBV Position: Q2 2026 in Review

Sumitomo Mitsui DS Asset Management increased its AbbVie (ABBV) stake by 1.1% in Q2 2026, buying an estimated $730K and bringing the position to 324,551 shares worth $81.7M. The position accounts for 0.56% of the portfolio, ranked #42.

Sumitomo Mitsui DS Asset Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sumitomo Mitsui DS Asset Management held 324,551 shares of AbbVie worth $81.7M as of Q2 2026.
  • Sumitomo Mitsui DS Asset Management bought 3,394 AbbVie shares in Q2 2026, an estimated $730K.
  • AbbVie made up 0.56% of Sumitomo Mitsui DS Asset Management's portfolio in Q2 2026, its #42 holding.
  • Sumitomo Mitsui DS Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.